PANews reported on August 13th that the board of directors of biopharmaceutical company LIXTE Biotechnology Holdings has approved a strategic capital allocation plan to invest up to 25% of the company's treasury in cryptocurrencies, including Bitcoin and other digital assets. The specific transaction size and timing will be determined based on market conditions and strategic considerations.
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.